Professor Risteárd Ó Laoide:

I will take that question.

The service developments for the year have been in the areas of surgical oncology, early diagnosis at rapid access clinics, radiation therapy, systemic therapy, cancer genetics and molecular diagnostics, survivorship and psycho-oncology, cancer prevention and enabling change in the governance of cancer services. We have recruited a total of 205 whole-time equivalents funded through this €20 million for service. Of those, 202 of the whole-time equivalents are now in position or there is recruitment in progress for them. There has been €14.4 million allocated with the remaining €5.6 million committed.